Patient P-01311
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
75%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 52 GI-04 recommended — GI Support Protocol GI-04
- Day 53 Patient accepted — Started GI-04 in the companion
- Day 59 ME-01 recommended — Monitoring Escalation ME-01
- Day 60 Patient accepted — Started ME-01 in the companion
- Day 61 No meaningful change — GI Support Protocol GI-04
- Day 63 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 51.
Primary contributors, last 14 days
- GI instability-16
- Inflammatory activity-7
- Nutritional resilience+3
What helped?
- GI Support Protocol GI-04Day 52Result: no meaningful change
- Monitoring Escalation ME-01Day 59Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
63%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 58 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
- WearableHRV 37 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 54
- Autonomic recovery ↓25
- WearableResting HR 81 bpm
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2 · butyrate capacity 23/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 38 ms
- Sleep
- 6.1 h
- Steps
- 5,979
- Resting HR
- 82 bpm
Daily log: GI score 58, nutritional resilience 39, adherence 43.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01751 | 69% | S14 | ME-01 | improved | 48 |
| P-01732 | 58% | S14 | ME-01 | improved | 45 |
| P-01595 | 56% | S14 | GI-04 | no change | 51 |
| P-01605 | 54% | S14 | ME-01 | improved | 41 |
| P-01454 | 53% | S14 | GI-04 | no change | 49 |
| P-01482 | 51% | S14 | GI-04 | improved | 47 |
| P-01782 | 51% | S14 | NP-02 | no change | 48 |
| P-01328 | 50% | S14 | SC-12 | no change | 49 |
| P-01760 | 50% | S14 | — | — | 42 |
| P-01465 | 49% | S14 | NP-02 | improved | 56 |
| P-01843 | 48% | S14 | SC-12 | no change | 45 |
| P-01396 | 47% | S14 | GI-04 | worsened | 51 |